These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1396734)

  • 21. Validation of Etest for seven antimicrobial agents using regulatory criteria for the assessment of antimicrobial susceptibility devices.
    Biedenbach DJ; Schermer IH; Jones RN
    Diagn Microbiol Infect Dis; 1997; 27(1-2):1-5. PubMed ID: 9127098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G; McKevitt M; Elborn JS; Tunney MM
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative in vitro activity of tobramycin, gentamicin, kanamycin, colistin, carbenicillin, and ticarcillin and clinical isolates of Pseudomonas aeruginosa: epidemiological and therapeutic implications.
    Dulong de Rosnay HL; Grimont PA; Dessaut B; Lesgouarres MT
    J Infect Dis; 1976 Aug; 134 Suppl():S50-6. PubMed ID: 823279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the E test, a novel method of quantifying antimicrobial activity.
    Brown DF; Brown L
    J Antimicrob Chemother; 1991 Feb; 27(2):185-90. PubMed ID: 2055809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Performance evaluation of VITEK 2 system in meropenem susceptibility testing of clinical Pseudomonas aeruginosa isolates].
    Acuner IC; Bayramoğlu G; Birinci A; Cekiç Cihan C; Bek Y; Durupınar B
    Mikrobiyol Bul; 2011 Jul; 45(3):411-21. PubMed ID: 21935774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 28. Susceptibility of nonfermentative gram-negative bacilli to tobramycin.
    Uwaydah M; Taqi-Eddin AR
    J Infect Dis; 1976 Aug; 134 Suppl():S28-32. PubMed ID: 823278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime activity against Pseudomonas aeruginosa: evaluation of Etest and two disc diffusion methods.
    Stes P; Goossens H
    J Antimicrob Chemother; 1996 Oct; 38(4):707-11. PubMed ID: 8937965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of antimicrobial susceptibilities of Pseudomonas aeruginosa isolates, with and without plaques, from two hospitals.
    Flournoy DJ; Belobraydic KA; Qadri SM
    Methods Find Exp Clin Pharmacol; 1986 Jun; 8(6):391-2. PubMed ID: 3090386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of clinical isolates of Pseudomonas aeruginosa for ribosomal resistance to tobramycin.
    Botha P; de Kock MJ; van Vuuren CJ; Fourie S; van Heerden C
    S Afr Med J; 1990 Sep; 78(5):258-9. PubMed ID: 2118277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymyxin B Etest
    Kulengowski B; Ribes JA; Burgess DS
    Clin Microbiol Infect; 2019 Jan; 25(1):92-95. PubMed ID: 29674129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR; White A; Elborn JS; Tunney MM
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL; Nelson LE; Shawar RM; Lin BB; Lockwood LG; Dirk JE; Miller GH; Burns JL; Garber RL
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
    Kelly LM; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):707-9. PubMed ID: 10382894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of minimum inhibitory concentration values determined by three antimicrobic dilution methods for Pseudomonas aeruginosa.
    Woolfrey BF; Fox JM; Quall CO
    Am J Clin Pathol; 1981 Jan; 75(1):39-44. PubMed ID: 6779623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of colistin stability in agar and comparison of four methods for MIC testing of colistin.
    Turlej-Rogacka A; Xavier BB; Janssens L; Lammens C; Zarkotou O; Pournaras S; Goossens H; Malhotra-Kumar S
    Eur J Clin Microbiol Infect Dis; 2018 Feb; 37(2):345-353. PubMed ID: 29177612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany.
    Schülin T
    J Antimicrob Chemother; 2002 Feb; 49(2):403-6. PubMed ID: 11815589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.